Literature DB >> 15087950

Alveolar soft-part sarcoma responsive to intensive chemotherapy.

H James Nickerson1, Teresa Silberman, F Stig Jacobsen, Bruce R Krawisz, Hope S Maki, Carola A S Arndt.   

Abstract

Alveolar soft-part sarcoma (ASPS) is a very rare malignant tumor, usually of the extremities, and is seen most often in adolescents and young adults. Surgical excision of the primary and pulmonary metastases has resulted in prolonged survival in some patients, but adjuvant radiation and/or chemotherapy are generally thought to be ineffective. The authors describe a 13-year-old patient with ASPS of an extremity who presented with multiple bilateral pulmonary metastases at diagnosis. Following intensive multiagent chemotherapy, pulmonary metastases showed in vivo evidence of tumor death. The patient has remained disease-free for 10 years following treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15087950     DOI: 10.1097/00043426-200404000-00004

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  4 in total

Review 1.  Primary alveolar soft part sarcoma of chest wall: a case report and review of the literature.

Authors:  Farhad Zamani; Mosadegh Jabbari; Seyed Maysom Alimohamadi; Ramin Shakeri; Zohreh Rostami; Behnoush Abedi; Mahshid Hormazdi; Reza Malekzadeh
Journal:  MedGenMed       Date:  2006-07-05

2.  Alveolar soft part sarcoma with brain metastases.

Authors:  Vinodh Vayara Perumall; Rahmat Harun; Pulivendhan Sellamuthu; Mohd Shariman Md Shah
Journal:  Asian J Neurosurg       Date:  2017 Jan-Mar

Review 3.  Autologous hematopoietic stem cell transplantation following high dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas.

Authors:  Frank Peinemann; Lesley A Smith; Carmen Bartel
Journal:  Cochrane Database Syst Rev       Date:  2013-08-07

4.  Alveolar soft-part sarcoma of the extremity: a case report.

Authors:  V Sidi; I Fragandrea; E Hatzipantelis; C Kyriakopoulos; A Papanikolaou; M Bandouraki; D E Koliouskas
Journal:  Hippokratia       Date:  2008       Impact factor: 0.471

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.